Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
Condition: Diabetic Gastroparesis; Idiopathic Gastroparesis
MeSH terms: Gastroparesis
Intervention: TAK-954; Placebo
Intervention description: TAK-954 IV infusion.; TAK-954 placebo-matching IV infusion.
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 36.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: No
Keywords: Drug Therapy

Summary:

      The purpose of this study is to evaluate the dose-dependent effects of TAK-954 on gastric
      emptying time of solids in participants with diabetic or idiopathic gastroparesis assessed by
      scintigraphy.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Has diabetes mellitus with symptoms of gastroparesis and previously documented gastric
             emptying delay or previously documented idiopathic gastroparesis in the last 5 years.

          2. Has a body mass index (BMI) greater than or equal to (>=) 16 and less than or equal to
             (<=) 40 kilogram per square meter (kg/m^2) at the Screening Visit.

        Exclusion Criteria:

          1. Has glycosylated hemoglobin (HbA1c) greater than (>) 12 percent (%).

          2. Has other structural diseases/conditions that affect the gastrointestinal (GI) system.

          3. Are unable to withdraw drugs known to alter GI transit 48 hours prior to the study.

          4. Has clinically significant abnormal baseline safety laboratory values.

          5. Has preexisting hepatic disease that meets Child-Pugh Class B (moderate; total score 7
             to 9 points) or C (severe; total score 10 to 15 points).

          6. Are without known preexisting hepatic disease who have 1 or more of the following:

               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 times the
                  upper limit of normal (ULN).

               -  Bilirubin >1.5 times the ULN unless due to Gilbert's syndrome.

               -  International normalized ratio (INR) >1.5 unless on anticoagulation therapy.

          7. Has QT intervals with Fridericia correction method (QTcF) interval (>=) 460
             millisecond (msec) or with other factors that increase the risk of QT prolongation or
             arrhythmic events at screening. Note: Participants with bundle branch block and a
             prolonged QTc interval, or with QTcF between 450 and 460 msec, should be reviewed by
             the Medical Monitor for potential inclusion.

          8. Has second or third degree atrioventricular (AV) block; AV disassociation; >5 beats of
             non-sustained VT at a rate >120 beats per minute (bpm); Electrocardiogram (ECG)
             changes consistent with acute myocardial ischemia or infarction.

          9. Has cardiac history that includes conditions requiring heart rate control (example,
             atrial fibrillation, atrial flutter, ventricular tachycardia, or other
             tachyarrhythmias).

         10. Has clinical evidence (including physical examination, ECG, clinical laboratory value
             and review of the medical history) of significant cardiovascular, respiratory,
             moderate or severe renal insufficiency (creatinine clearance <=60 mL/min),
             hematological, neurological, or psychiatric disease, or other disease that interferes
             with the objectives of the study.

         11. If female, are pregnant or lactating or intending to become pregnant before
             participating in this study, during the study, and 4 to 5 days (5 half-lives) PLUS 30
             days after last dose of the study drug; or intending to donate ova during such time
             period.

         12. Are considered by the investigator to be alcoholics not in remission or known
             substance abusers. Have a history of alcohol consumption exceeding 2 standard drinks
             per day on average (1 glass is approximately equivalent to: beer [354 milliliter per
             [mL/] 12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 mL/1 ounce] per
             day).